Eli Lilly and Company has announced that Leena Gandhi, M.D., Ph.D will join Lilly Oncology on June 25, 2018 to lead immuno-oncology medical development. 

Dr. Gandhi is currently the director of Thoracic Medical Oncology and an associate professor of medicine at the New York University (NYU) School of Medicine. After joining Lilly, she will lead a team of scientists that oversees the Lilly Oncology immunotherapy portfolio. She will report to Kimberly Blackwell, M.D., vice president of Early Phase Development and Immuno-oncology.

“Dr. Gandhi is highly regarded for her experience in thoracic oncology and immunotherapy, having worked in early drug development at Dana-Farber Cancer Institute and now leading the Thoracic Medical Oncology Program at NYU,” said Blackwell. “We know that her expertise and innovative thinking will lead to significant progress for patients facing cancer through the use of immune therapies. We are thrilled to have Dr. Gandhi join us at Lilly.”

Dr. Gandhi graduated from the NYU School of Medicine and completed her fellowship at Dana-Farber Cancer Institute (DFCI). She worked in the Early Drug Development Center at DFCI and in the Thoracic Oncology Program as the Head of Clinical Trials until 2016, at which point she joined NYU Perlmutter Cancer Center as the Director of Thoracic Medical Oncology.